Comments
Marksans Pharma on Tuesday said it has received an establishment inspection report (EIR) from the US health regulator for company’s manufacturing facility in the US.
In a regulatory filing, the company announced “receipt of the EIR from US Food and Drug Administration (USFDA) in respect of inspection of company’s manufacturing facility Time-Cap Laboratories Inc. located at Farmingdale, New York, USA carried out from December 5 to December 18, 2019“.
The shares of the company were trading at ₹23.20 apiece on BSE, up 4.98 per cent from the previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.